A higher dose of liraglutide, up to 3 mg daily (Saxenda), has been approved by the US FDA for weight management in certain obese or overweight individuals
F., Leech, C
Tolerance development: Nausea, flushing, and erectile effects diminish significantly by day 1014 of consistent dosing due to MC4R desensitization
Obesity is a chronic relapsing, progressive disease, and the approval of semaglutide can be revolutionary for obesity
Ongoing monitoring: Regular check-ups allow healthcare providers to adjust dosages, monitor progress, and address any side effects or concerns
Adequate hydration supports kidney function, helps manage potential side effects, and can help distinguish between hunger and thirst